Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: A prospective, open-label pilot study

Clinical Interventions in Aging

Volumn 11, Issue , 2016, Pages 29-36

  Ohnuma, Tohru ^a   Toda, Aiko ^a   Kimoto, Ayako ^a   Takebayashi, Yuto ^a   Higashiyama, Ryoko ^a   Tagata, Yuko ^a   Ito, Masanobu ^a   Ota, Tsuneyoshi ^a   Shibata, Nobuto ^a   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Alzheimer s disease; Apolipoprotein E epsilon 4; Cognitive function; Ketone; Medium chain triglycerides

Indexed keywords

3 HYDROXYBUTYRIC ACID; AC 1202; ACETOACETIC ACID; APOLIPOPROTEIN E4; DONEPEZIL; GALANTAMINE; KETONE BODY; MEDIUM CHAIN TRIACYLGLYCEROL; MEMANTINE; RIVASTIGMINE; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ALLELE; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BRAIN INFARCTION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; JAPANESE (PEOPLE); LOW DRUG DOSE; MALE; MINI MENTAL STATE EXAMINATION; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT COMPLIANCE; PILOT STUDY; UNSPECIFIED SIDE EFFECT; AGED; BLOOD; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DRUG EFFECTS; ELEMENTAL DIET; JAPAN; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD, FORMULATED; HUMANS; JAPAN; KETONE BODIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PILOT PROJECTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84955309775     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S95362     Document Type: Article

References (29)

1. Marques SC, Oliveira CR, Outeiro TF, Pereira CM. Alzheimer's disease: the quest to understand complexity. J Alzheimers Dis. 2010; 21(2): 373-383.
2. Marques SC, Oliveira CR, Pereira CM, Outeiro TF. Epigenetics in neurodegeneration: a new layer of complexity. Prog Neuropsychop­harmacol Biol Psychiatry. 2011; 35(2): 348-355.
3. Mancuso C, Bates TE, Butterfield DA, et al. Natural antioxidants in Alzheimer's disease. Expert Opin Investig Drugs. 2007; 16(12): 1921-1931.
4. Cole GM, Lim GP, Yang F, et al. Prevention of Alzheimer's disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging. 2005; 26 Suppl 1: 133-136.
5. Rossi L, Mazzitelli S, Arciello M, Capo CR, Rotilio G. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem Res. 2008; 33(12): 2390-2400.
6. Thomas P, Wang YJ, Zhong JH, et al. Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer's disease. Mutat Res. 2009; 661(1-2): 25-34.
7. Henderson ST, Poirier J. Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study. BMC Med Genet. 2011; 12: 137.
8. Henderson ST. Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics. 2008; 5(3): 470-480.
9. Roman MW. Axona (Accera, Inc): a new medical food therapy for persons with Alzheimer's disease. Issues Ment Health Nurs. 2010; 31(6): 435-436.
10. Scheltens P, Kamphuis PJ, Verhey FR, et al. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement. 2010; 6(1): 1-10. e11.
11. Thaipisuttikul P, Galvin JE. Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease. Clin Pract (Lond). 2012; 9(2): 199-209.
12. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7(3): 137-152.
13. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995; 273(12): 942-947.
14. Small GW, La Rue A, Komo S, Kaplan A, Mandelkern MA. Predictors of cognitive change in middle-aged and older adults with memory loss. Am J Psychiatry. 1995; 152(12): 1757-1764.
15. Small GW, Kuhl DE, Riege WH, et al. Cerebral glucose metabolic patterns in Alzheimer's disease. Effect of gender and age at dementia onset. Arch Gen Psychiatry. 1989; 46(6): 527-532.
16. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009; 6: 31.
17. Reger MA, Henderson ST, Hale C, et al. Effects of β-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. 2004; 25(3): 311-314.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3): 189-198.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7): 939-944.
20. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997; 32(9): 920-924.
21. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983; 19(3): 448-450.
22. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991; 337(8750): 1158-1159.
23. Kubo M, Hata J, Doi Y, Tanizaki Y, Iida M, Kiyohara Y. Secular trends in the incidence of and risk factors for ischemic stroke and its subtypes in Japanese population. Circulation. 2008; 118(25): 2672-2678.
24. St-Onge MP, Bosarge A, Goree LL, Darnell B. Medium chain triglyc­eride oil consumption as part of a weight loss diet does not lead to an adverse metabolic profile when compared to olive oil. J Am Coll Nutr. 2008; 27(5): 547-552.
25. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF Jr. Brain metabolism during fasting. J Clin Invest. 1967; 46(10): 1589-1595.
26. Hasselbalch SG, Madsen PL, Hageman LP, et al. Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. Am J Physiol. 1996; 270(5 Pt 1): E746-E751.
27. Cunnane S, Nugent S, Roy M, et al. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition. 2011; 27(1): 3-20.
28. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathologi­cal correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol. 1996; 39(1): 62-70.
29. Hostage CA, Roy Choudhury K, Doraiswamy PM, Petrella JR. Dissecting the gene dose-effects of the APOE ε4 and ε2 alleles on hippocampal volumes in aging and Alzheimer's disease. PLoS One. 2013; 8(2): e54483.